Abstract
Using a radioimmunoassay we have determined serum levels of the carcinoma-associated antigen CA-50 in 266 patients with colorectal cancer. Elevated CA-50 levels were found in Dukes’ A (15%), Dukes’ B (43%), Dukes’ C (31%) and Dukes’ D (65%). Patients who had developed a recurrence had 66% elevated levels. 25% of resected patients with no evidence of disease also had elevated CA-50 levels. From 139 patients operated on for a Dukes’ A-C, a rise in CA-50 levels from the pre- to the 6–9 month post-operative sample was demonstrated in 12 cases in the absence of any clinical evidence for a recurrence. On follow-up, a recurrence later developed in all these cases with lead times of CA-50 titre rises ranging from 5 to 40 months. A rise in CA-50 levels after resection of a Dukes’ A-C is indicative of a recurrence and may precede any clinical evidence of disease by several months or years. Data is also presented from 552 cases with colorectal cancer analysed with a immunoradiometric assay.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Holmgren J (ed):Tumor Marker Antigens. Lund, Studentlitteratur (1985).
Gold P, Freedman S O: Specific carcinoembryonic antigens in the human digestive system.J exp Med 121, 439 (1965).
Holyoke E D, Evans J T, Mittelman A: Carcino-embryonic antigen as a tumor marker, in Chu T M (ed):Biochemical Marker for Cancer, pp. 61–80. New York, Marcel Dekker (1982).
Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity.Nature 257, 495 (1975).
Koprowski M, Steplenski Z, Mitchell K, Herlyn M, Herlun D, Fulner P: Colorectal carcinoma antigens detected by hyridoma antibodies.Som Cell Genet 5, 957 (1979).
Lindholm L, Holmgren J, Svennerholm L: Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides.Int Archs Allergy appl Immun 71, 178 (1983).
Hakomori S I: Glycosphingolipids in cellular interaction, differentiation and oncogenesis.Ann Rev Biochem 50, 733 (1981).
Nilsson O, Lindholm L. Persson Bet al.: Tissue distribution and concentration of a monoclonal antibody defined tumor-associated ganglioside antigen, in Chester M A, Heinegård D, Lundblad A, Svensson S (eds):Glycoconjugates: Proceedings of 7th International Symposium. Lund, Lund University Symposium Secretariat, pp. 852–853 (1983).
Magnani J, Bookhaus M, Smith Det al.: A monosialoganglioside is a monoclonal antibody defined antigen of colon carcinoma.Science 212, 55 (1981).
Månsson J E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L: Chemical structures of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. BBA834, 110 (1985).
Hammarström S: Chemistry and immunology of CEA, CA 19-9 and CA-50, in Holmgren J (ed):Tumour Marker Antigens, pp. 34–51. Lund, Studentlitteratur (1985).
Hahomori S I: Sphingolipid biochemistry, in Hahomori S I, Kaufer J N (eds):Handbook of Lipid Research, vol. 3, pp. 327–379. New York, Plenum. Press (1983).
Holmgren J, Lindholm L, Persson B.et al.: Detection by monoclonal antibody of carbohydrate antigen CA-50 in serum of patients with carcinoma.Br Med J 288, 1479 (1984).
CanAG CA-50 IRMA forin vitro diagnostic use. Stena Diagnostics, Gothenburg (1987).
Lindholm L, Jansson E-L, Oskarsson K, Nilsson O, Karlsson B: Immunoradiometric assay (IRMA) for the determination of CA-50 antigen, inProceedings from XIV Annual meeting ISOBM, Helsinki, Finland (1986).
Bruhn H D, Broers H, Euler Het al.: CA-50 in Serum von Karzinom-Patienten.Dt med Wschr 111, 34,1267 (1986).
Jalanko H. Haglund C, Roberts P J, Kuusela P: Tumor markers in gastrointestinal cancers, in Holmgren J (ed):Tumor Marker Antigens, pp. 114–122. Lund, Studentlitteratur (1985).
Paganuzzi M, Marroni P, Boccardoet al.: Clinical evaluation of CA-50 in sera of patients with different tumors, in Holmgren J (ed):Tumor Marker Antigens, pp. 134–145. Lund, Studentlitteratur (1985).
Habib N. Hershman M, Papp Let al.: The detection of colorectal carcinomas with the use of CA-50 radioimmunoassay inhibition test.Int J colorect Dis 1, 186 (1986).
Stena Diagnostics, CanAg CA-50 Radioimmunoassay. A radioimmunoassay (RIA) for the detection of the human carcinoma-associated antigen CA-50 in serum. Stena Diagnostics, Gothenburg, Sweden.
Dukes, C E, Bussey H I R. The spread of rectal cancer and its effect on prognosis.Br J Cancer 12, 309 (1985).
Gronowitz M, Kilander A F, Holmgren J, Lindholm L. Persson B, Åhrén C: Serum levels of the carcinoma-associated antigen CA-50 in ulcerative colitis.Scand J Gastroent (accepted for publication).
Nilsson O, Dahlén U, Karlsson B, and Lindholm L: TR-FIA determination of cancer antigen CA-50, inProceedings from XIV Annual meeting ISOBM, Helsinki, Finland (1986).
Del Villano B V, Brennan S, Broch Pet al.: Radioimmunoassay for a monoclonal antibody-defined tumor marker, CA 10-9.Clin Chem 29, 549 (1983).
Nilsson O, Månsson J-E, Lindholm L. Holmgren J, Svennerholm L: Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody.FEBS Letters 182, 398 (1985).
Nilsson L-Å, Gisslén H, Lindholm A. Lindholm L, Mobacken H: Identification of basal cell carcinomas by means of monoclonal antibodies C 50 and C 241 against the carcinoma associated carbohydrate structures sialylated Lea and Si-lactotetraose.J Derm surg Oncol (in press).
Haglund C, Kuusela P, Jalanko H, Roberts P J: Serum CA-50 as a tumor marker in pancreatic cancer. A comparasion with CA 19-9.Int J Cancer (in press).
Ritto RE Jr, Del Villano B C, Go V L Wet al.: Ritts initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.Int J Cancer 33, 339 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persson, B.E., Ståhle, E., Påhlman, L. et al. A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer. Med. Oncol. & Tumor Pharmacother. 5, 165–171 (1988). https://doi.org/10.1007/BF02986440
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02986440